7-hydroxystaurosporine
Cancer Of Unknown Primary Site
Explore 18 assets in Cancer Of Unknown Primary Site →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00047242CT.gov UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00042861CT.gov UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors | — | Completed | — | — | — |
NCT00045500CT.gov UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma | — | Completed | — | — | — |
NCT00036777CT.gov UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00031681CT.gov 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | — | Completed | — | — | — |
NCT00012194CT.gov 7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors | — | Terminated | — | — | — |
NCT00006464CT.gov UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT00004059CT.gov Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors | — | Completed | — | — | — |
NCT00003289CT.gov UCN-01 in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer Of Unknown Primary Site
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 7-hydroxystaurosporine (this asset) | National Cancer Institute (NCI) | P1 | B · 58 |
| Nepenthe | M.D. Anderson Cancer Center | P4 | BBB |
| Amifostine | M.D. Anderson Cancer Center | P4 | BBB |
| Etoposide | University of California, Davis | P2/3 | BBB |
| Dexasone | Alliance for Clinical Trials in Oncology | P3 | BBB |
| Nivestim | National Institutes of Health Clinical Center (CC) | P3 | BBB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P3 | BBB |
| Docetaxel | University of Wisconsin, Madison | P2 | BBB |
| Sargramostim | Barbara Ann Karmanos Cancer Institute | P2 | BBB |
+42 more in the Cancer Of Unknown Primary Site cohort
Other indications for 7-hydroxystaurosporine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P2 | BB · 64 |
| Small Cell Lung Carcinoma | — | P2 | BB · 64 |
| Lymphoma | — | P1/2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 7-hydroxystaurosporine in Cancer Of Unknown Primary Site. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/7-hydroxystaurosporine-cancer-of-unknown-primary-site
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →